Journal
BIOMATERIALS
Volume 34, Issue 7, Pages 1772-1780Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2012.11.032
Keywords
Mesenchymal stem cells (MSCs); Mesoporous silica nanoparticles (MSNs); Cell engineering; Multimodal imaging; Targeted delivery
Funding
- National Basic Research Program of China (973 program) [2013CB733802]
- National Science Foundation of China (NSFC) [81201086, 81201129, 81100234, 81028009]
- Chinese Academy of Sciences professorship for Senior International Scientists [2011T2J06]
- Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)
- Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM)
Ask authors/readers for more resources
Stem cell engineering, the manipulation and control of cells, harnesses tremendous potential for diagnosis and therapy of disease; however, it is still challenging to impart multifunctionalization onto stem cells to achieve both. Here we describe a mesenchymal stem cell (MSC)-based multifunctional platform to target orthotopic glioblastoma by integrating the tumor targeted delivery of mesenchymal stem cells and the multimodal imaging advantage of mesoporous silica nanoparticles (MSNs). Rapid cellular uptake, long retention time and stability of particles exemplify the potential that the combination of MSNs and MSCs has as a stem cell-based multifunctional platform. Using such a platform, we verified tumor-targeted delivery of MSCs by in vivo multimodal imaging in an orthotopic U87MG glioblastoma model, displaying higher tumor uptake than particles without MSCs. As a proof-of-concept, this MSC platform opens a new vision for multifunctional applications of cell products by combining the superiority of stem cells and nanoparticles for actively targeted delivery. (C) 2012 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available